CY1122551T1 - Ενωσεις για τη θεραπεια της παχυσαρκιας και μεθοδοι χρησης αυτων - Google Patents
Ενωσεις για τη θεραπεια της παχυσαρκιας και μεθοδοι χρησης αυτωνInfo
- Publication number
- CY1122551T1 CY1122551T1 CY20191100155T CY191100155T CY1122551T1 CY 1122551 T1 CY1122551 T1 CY 1122551T1 CY 20191100155 T CY20191100155 T CY 20191100155T CY 191100155 T CY191100155 T CY 191100155T CY 1122551 T1 CY1122551 T1 CY 1122551T1
- Authority
- CY
- Cyprus
- Prior art keywords
- obese
- morbidly
- patient
- methods
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Στο παρόν περιγράφονται παράγοντες απώλειας βάρους, οι οποίοι περιλαμβάνουν ενώσεις που ορίζονται από τον Τύπο I ή ένα φαρμακευτικά αποδεκτό άλας ή προφάρμακο αυτών, συνθέσεις που περιλαμβάνουν αυτούς και μέθοδοι χρήσης αυτών. Σε κάποιες υλοποιήσεις η ένωση είναι η Βιθαφερίνη Α. Σε άλλες υλοποιήσεις η ένωση είναι ένα προϊόν προσθήκης Michael της Βιθαφερίνης Α. ΟΙ ενώσεις μπορούν να χορηγηθούν για να προκαλέσουν απώλεια βάρους σε έναν προ-παχύσαρκο, παχύσαρκο ή νοσηρά παχύσαρκο ασθενή, μείωση του σωματικού λίπους σε έναν προ-παχύσαρκο, παχύσαρκο ή νοσηρά παχύσαρκο ασθενή, μείωση της λήψης τροφής σε έναν προ-παχύσαρκο, παχύσαρκο ή νοσηρά παχύσαρκο ασθενή, βελτίωση της ομοιόστασης γλυκόζης σε έναν προ-παχύσαρκο. παχύσαρκο ή νοσηρά παχύσαρκο ασθενή ή συνδυασμούς αυτών.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361908998P | 2013-11-26 | 2013-11-26 | |
| PCT/US2014/067393 WO2015081093A1 (en) | 2013-11-26 | 2014-11-25 | Compounds for the treatment of obesity and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122551T1 true CY1122551T1 (el) | 2021-01-27 |
Family
ID=52134396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100155T CY1122551T1 (el) | 2013-11-26 | 2019-02-05 | Ενωσεις για τη θεραπεια της παχυσαρκιας και μεθοδοι χρησης αυτων |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20160375039A1 (el) |
| EP (1) | EP3074033B1 (el) |
| JP (2) | JP6672157B2 (el) |
| AU (2) | AU2014354831B2 (el) |
| CA (1) | CA2931826C (el) |
| CY (1) | CY1122551T1 (el) |
| DK (1) | DK3074033T3 (el) |
| ES (1) | ES2709976T3 (el) |
| HR (1) | HRP20190219T1 (el) |
| HU (1) | HUE042196T2 (el) |
| LT (1) | LT3074033T (el) |
| PL (1) | PL3074033T3 (el) |
| PT (1) | PT3074033T (el) |
| RS (1) | RS58422B1 (el) |
| SI (1) | SI3074033T1 (el) |
| TR (1) | TR201901299T4 (el) |
| WO (1) | WO2015081093A1 (el) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170209408A1 (en) * | 2014-04-03 | 2017-07-27 | The Children's Medical Center Corporation | Hsp90 inhibitors for the treatment of obesity and methods of use thereof |
| CN106008657B (zh) * | 2016-05-20 | 2017-11-21 | 天津中医药大学 | 苦蘵苦素i及提取方法及用途 |
| IT201800005336A1 (it) * | 2018-05-14 | 2019-11-14 | Composizioni per uso nel trattamento dell’obesità | |
| US20210106525A1 (en) * | 2019-10-11 | 2021-04-15 | Massachusetts Institute Of Technology | Formulations for gastrointestinal delivery of oligonucleotides |
| CN113599502A (zh) * | 2021-07-22 | 2021-11-05 | 廖儒佳 | 一种醉茄素a和瘦素的组合物及其在制备预防和或治疗出血性脑卒中药物中的应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA791659B (en) | 1978-04-17 | 1980-04-30 | Ici Ltd | Process and apparatus for spraying liquid |
| GB8504253D0 (en) | 1985-02-19 | 1985-03-20 | Ici Plc | Electrostatic spraying apparatus |
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| MY107937A (en) | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US6429290B1 (en) | 1994-08-17 | 2002-08-06 | The Rockefeller University | OB polypeptides, modified forms and derivatives |
| US6350730B1 (en) | 1994-08-17 | 2002-02-26 | The Rockefeller University | OB polypeptides and modified forms as modulators of body weight |
| US6001968A (en) | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
| US5827734A (en) | 1995-01-20 | 1998-10-27 | University Of Washington | Materials and methods for determining ob protein in a biological sample |
| US5532336A (en) | 1995-01-31 | 1996-07-02 | Eli Lilly And Company | Anti-obesity proteins |
| US5521283A (en) | 1995-01-31 | 1996-05-28 | Eli Lilly And Company | Anti-obesity proteins |
| US5552523A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5552524A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5552522A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| WO1996040912A1 (en) | 1995-06-07 | 1996-12-19 | Amgen Inc. | Ob protein compositions and method |
| CZ416797A3 (cs) | 1995-06-30 | 1998-06-17 | Eli Lilly And Company | Použití leptinu nebo leptonových mimetik pro výrobu léčiv pro léčení nebo prevenci diabetes mellitus a kompozice s jeho obsahem |
| CA2229450A1 (en) | 1995-08-17 | 1997-02-27 | Amgen Inc. | Methods of reducing or maintaining reduced levels of blood lipids using ob protein compositions |
| US20030040467A1 (en) | 1998-06-15 | 2003-02-27 | Mary Ann Pelleymounter | Ig/ob fusions and uses thereof. |
| CA2358862A1 (en) | 1995-11-22 | 1997-05-29 | Amgen Inc. | Methods of increasing lean tissue mass using ob protein compositions |
| US6936439B2 (en) | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
| AU2670897A (en) | 1996-04-04 | 1997-10-29 | Amgen, Inc. | Fibulin pharmaceutical compositions and related methods |
| JP2000514422A (ja) * | 1996-06-20 | 2000-10-31 | メルク エンド カンパニー インコーポレーテッド | 肥満のための遺伝子治療 |
| JP2001501177A (ja) | 1996-08-30 | 2001-01-30 | アムジエン・インコーポレーテツド | Ｏｂタンパク質受容体をアップレギュレートすることによりｏｂタンパク質に対する個体の感受性を増加させる方法 |
| WO1998012224A1 (en) | 1996-09-20 | 1998-03-26 | Hoechst Aktiengesellschaft | Use of leptin antagonists for treating insulin resistance in type ii diabetes |
| DE69730093T2 (de) | 1996-10-31 | 2006-07-20 | Takeda Pharmaceutical Co. Ltd. | Zubereitung mit verzögerter Freisetzung |
| PL194159B1 (pl) | 1996-12-20 | 2007-05-31 | Amgen Inc | Proteina fuzyjna OB, kompozycja farmaceutyczna zawierająca tę proteinę i zastosowanie tej proteiny, a także kwas nukleinowy kodujący tę proteinę, wektor zawierający ten kwas nukleinowy, komórka gospodarza zawierająca ten wektor oraz sposób wytwarzania proteiny fuzyjnej OB |
| ES2183351T3 (es) | 1997-04-17 | 2003-03-16 | Amgen Inc | Composicones que comprenden conjugados de proteina ob humana activa estable con una cadena fc de inmunoglobulinas y metodos. |
| TR199902980T2 (xx) | 1997-06-06 | 2000-05-22 | Smithkline Beecham P.L.C. | Diabetin tedavisi i�in leptin antagonistlerinin kullan�m�. |
| US7052678B2 (en) | 1997-09-15 | 2006-05-30 | Massachusetts Institute Of Technology | Particles for inhalation having sustained release properties |
| US6541033B1 (en) | 1998-06-30 | 2003-04-01 | Amgen Inc. | Thermosensitive biodegradable hydrogels for sustained delivery of leptin |
| ATE280588T1 (de) | 1998-08-10 | 2004-11-15 | Amgen Inc | Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren |
| AU6396999A (en) | 1998-10-02 | 2000-04-26 | Amgen, Inc. | Method to determine a predisposition to leptin treatment |
| US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
| AU781460B2 (en) | 1999-02-12 | 2005-05-26 | Amgen, Inc. | Glycosylated leptin compositions and related methods |
| WO2003034996A2 (en) | 2001-10-22 | 2003-05-01 | Amgen, Inc. | Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment |
| AU2003290563A1 (en) | 2002-10-31 | 2004-05-25 | Clf Medical Technology Acceleration Program, Inc. | Leptin-related peptides |
| JP4585186B2 (ja) * | 2003-07-31 | 2010-11-24 | 杏林製薬株式会社 | 肥満、糖尿病及び脂質代謝異常の新規な予防又は治療剤 |
| US20100120747A1 (en) * | 2006-06-23 | 2010-05-13 | Laboratorios Del Dr. Esteve, S.A. | Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity |
| WO2010030395A2 (en) * | 2008-09-15 | 2010-03-18 | Whitehead Institute For Biomedical Research | Withaferin a analogs and uses thereof |
| WO2010053655A2 (en) * | 2008-11-07 | 2010-05-14 | University Of Kansas | Therapeutic methods with withaferin a and analogs |
| WO2012106393A2 (en) * | 2011-02-01 | 2012-08-09 | University Of Kansas | Withanolide isolated from physalis longifolia and analogs and methods of use thereof |
-
2014
- 2014-11-25 AU AU2014354831A patent/AU2014354831B2/en not_active Ceased
- 2014-11-25 TR TR2019/01299T patent/TR201901299T4/tr unknown
- 2014-11-25 RS RS20190124A patent/RS58422B1/sr unknown
- 2014-11-25 LT LTEP14816018.7T patent/LT3074033T/lt unknown
- 2014-11-25 CA CA2931826A patent/CA2931826C/en active Active
- 2014-11-25 HU HUE14816018A patent/HUE042196T2/hu unknown
- 2014-11-25 PT PT14816018T patent/PT3074033T/pt unknown
- 2014-11-25 ES ES14816018T patent/ES2709976T3/es active Active
- 2014-11-25 WO PCT/US2014/067393 patent/WO2015081093A1/en active Application Filing
- 2014-11-25 PL PL14816018T patent/PL3074033T3/pl unknown
- 2014-11-25 JP JP2016554826A patent/JP6672157B2/ja active Active
- 2014-11-25 EP EP14816018.7A patent/EP3074033B1/en active Active
- 2014-11-25 US US15/039,743 patent/US20160375039A1/en not_active Abandoned
- 2014-11-25 SI SI201431046T patent/SI3074033T1/sl unknown
- 2014-11-25 DK DK14816018.7T patent/DK3074033T3/en active
-
2018
- 2018-01-23 AU AU2018200517A patent/AU2018200517B2/en not_active Ceased
-
2019
- 2019-02-01 HR HRP20190219TT patent/HRP20190219T1/hr unknown
- 2019-02-05 CY CY20191100155T patent/CY1122551T1/el unknown
- 2019-12-16 JP JP2019226600A patent/JP2020059744A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RS58422B1 (sr) | 2019-04-30 |
| CA2931826A1 (en) | 2015-06-04 |
| TR201901299T4 (tr) | 2019-02-21 |
| JP6672157B2 (ja) | 2020-03-25 |
| PT3074033T (pt) | 2019-02-08 |
| ES2709976T3 (es) | 2019-04-22 |
| US20160375039A1 (en) | 2016-12-29 |
| JP2016537431A (ja) | 2016-12-01 |
| AU2018200517B2 (en) | 2019-12-19 |
| CA2931826C (en) | 2021-11-16 |
| EP3074033A1 (en) | 2016-10-05 |
| AU2014354831A1 (en) | 2016-06-09 |
| HRP20190219T1 (hr) | 2019-03-22 |
| DK3074033T3 (en) | 2019-02-11 |
| JP2020059744A (ja) | 2020-04-16 |
| AU2014354831B2 (en) | 2017-10-26 |
| WO2015081093A1 (en) | 2015-06-04 |
| HUE042196T2 (hu) | 2019-06-28 |
| PL3074033T3 (pl) | 2019-08-30 |
| EP3074033B1 (en) | 2018-11-07 |
| LT3074033T (lt) | 2019-02-25 |
| SI3074033T1 (sl) | 2019-03-29 |
| AU2018200517A1 (en) | 2018-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122551T1 (el) | Ενωσεις για τη θεραπεια της παχυσαρκιας και μεθοδοι χρησης αυτων | |
| CY1120334T1 (el) | Υποκατεστημενης 3-αλλογονοαλυλαμινης αναστολεις ssao και χρησεις αυτων | |
| CY1124000T1 (el) | Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη | |
| CY1123388T1 (el) | Υποκατεστημενου νικοτινιμιδιου αναστολεις της βτκ και παρασκευη αυτων και χρηση στη θεραπεια καρκινου, φλεγμονης και αυτοανοσης ασθενειας | |
| CY1121763T1 (el) | Παραγωγα διπυραζολιου ως αναστολεις jak | |
| CY1123626T1 (el) | Ετεροκυκλικοι αναστολεις πρωτεϊνικης κινασης | |
| CY1120104T1 (el) | Αναστολεις της syk | |
| CY1121549T1 (el) | Ενωσεις 1-αρυλκαρβονυλ-4-oξυ-πιπεριδινης χρησιμες για την αγωγη νευροεκφυλιστικων παθησεων | |
| CY1119487T1 (el) | Αναστολεις κιναζολινης των ενεργοποιητικων μεταλλαγμενων μορφων του υποδοχεα του επιδερμικου αυξητικου παραγοντα | |
| CY1119433T1 (el) | Αμινο-υποκατεστημενες ιμιδαζοπυριδαζινες | |
| CY1117559T1 (el) | Ενωση ινδολιου και φαρμακευτικη χρηση αυτου | |
| DOP2015000308A (es) | Inhibidores de bromodominios | |
| EA202090860A1 (ru) | Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn | |
| DOP2015000240A (es) | 3- pirimidin- 4- il- oxazolidin- 2- onas como inhibidores de idh mutante | |
| EA201390766A1 (ru) | БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПОЛУЧЕНИЯ | |
| EA201592250A1 (ru) | Пиразолопирролидиновые производные и их применение в лечение заболеваний | |
| EA201291300A1 (ru) | Производные нафт-2-илуксусной кислоты для лечения спида | |
| EA201500300A1 (ru) | Способы применения с-мет-модуляторов | |
| EA201592256A1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
| CY1119007T1 (el) | Συνθεσεις και μεθοδοι αγωγης πνευμονικης υπερτασης | |
| CY1120378T1 (el) | Υποκατεστημενα παραγωγα του διφαινυλο βουτανοϊκου φωσφονικου οξεος ως αναστολεις νερ (ουδετερης ενδοπεπτιδασης) | |
| EA201300862A1 (ru) | Ингибирование il17 и ifn-гамма для лечения аутоиммунного воспаления | |
| CY1118947T1 (el) | Ασυμμετρες ουριες και ιατρικες χρησεις αυτων | |
| CR20120040A (es) | Derivados de 17-hidroxi-17-pentafluoroetil-estra-4,9(10)-dien-11-arilo, procedimientos para su preparación y su uso para el tratamiento de enfermedades | |
| CY1121166T1 (el) | Ενωσεις για τη θεραπεια παχυσαρκιας και μεθοδοι χρησης αυτων |